chr3-37047652-T-C
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM2PM5PP3_StrongPP5_Very_Strong
The NM_000249.4(MLH1):c.1865T>C(p.Leu622Pro) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 13/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. L622H) has been classified as Pathogenic.
Frequency
Consequence
NM_000249.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MLH1 | NM_000249.4 | c.1865T>C | p.Leu622Pro | missense_variant | 16/19 | ENST00000231790.8 | NP_000240.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MLH1 | ENST00000231790.8 | c.1865T>C | p.Leu622Pro | missense_variant | 16/19 | 1 | NM_000249.4 | ENSP00000231790 | P1 |
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 31
ClinVar
Submissions by phenotype
Lynch syndrome Pathogenic:1
Pathogenic, reviewed by expert panel | curation | International Society for Gastrointestinal Hereditary Tumours (InSiGHT) | Feb 21, 2019 | Multifactorial likelihood analysis posterior probability >0.99 (1.000) - |
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jun 03, 2022 | This sequence change replaces leucine, which is neutral and non-polar, with proline, which is neutral and non-polar, at codon 622 of the MLH1 protein (p.Leu622Pro). This variant is not present in population databases (gnomAD no frequency). For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Leu622 amino acid residue in MLH1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 11748856, 17510385, 20858721, 23403630, 24362816). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Experimental studies have shown that this missense change affects MLH1 function (PMID: 30998989). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt MLH1 protein function. ClinVar contains an entry for this variant (Variation ID: 89911). This missense change has been observed in individual(s) with clinical features of Lynch syndrome (PMID: 1749856, 21404117; Invitae). - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 21, 2019 | The p.L622P variant (also known as c.1865T>C), located in coding exon 16 of the MLH1 gene, results from a T to C substitution at nucleotide position 1865. The leucine at codon 622 is replaced by proline, an amino acid with similar properties. This alteration has been reported in a patient with breast and colorectal cancer who met Bethesda criteria for Lynch syndrome and whose colorectal tumor showed loss of MLH1 and PMS2 proteins on immunohistochemical (IHC) analysis (Koehler U et al. Cancer Genet. Cytogenet., 2007 May;175:81-4). This alteration was also reported in an individual diagnosed with colon cancer at 43 who met Amsterdam II criteria for Lynch syndrome. This individual's colon tumor displayed high microsatellite instability (MSI-H) with loss of both MLH1/PMS2 on IHC analysis and co-occurrence with another MLH1 missense alteration was identified, p.A623S, but the phase (whether in cis or trans) was not reported (Hardt K et al. Fam. Cancer, 2011 Jun;10:273-84). This alteration was also identified as somatic in a MSI-H colon tumor that displayed loss of MLH1 and PMS2 on IHC analysis (Ambry internal data). Based on an internal structural assessment, this alteration leads to destabilization of the C-terminal domain. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. In addition, this alteration is predicted to be deleterious by MAPP-MMR in silico analyses (Chao EC et al. Hum. Mutat. 2008 Jun;29:852-60) and pathogenic by the PON-MMR prediction tool (Ali H et al. Hum. Mutat., 2012 Apr;33:642-50). Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at